Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Accounting Officer | May 12, 2022 | May 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date May 12, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 219,954 |
Reported balance
After 2022-05-12 transaction · row 1
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 150,000 · Balance 219,954 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The restricted stock units will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The restricted stock units will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2022 Filed May 16, 2022 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004030 · primarydocument.xml · nonDerivative · entry 1 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,954 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The restricted stock units will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 70,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002164 · primarydocument.xml · derivative · entry 3 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 40,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002164 · primarydocument.xml · nonDerivative · entry 2 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,954 F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will become vested on the first anniversary of the grant date; and the remaining 2/3 of the Shares will vest in substantially equal quarterly installments thereafter, at the beginning of each of the following eight calendar quarters, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 3,946 | $2.15 | $8,502.84 |
DisclosureSEC source: 0001562180-22-002164 · primarydocument.xml · nonDerivative · entry 1 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,121 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 5,833 | $2.29 | $13,335.40 |
DisclosureSEC source: 0001562180-22-000236 · primarydocument.xml · nonDerivative · entry 1 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,067 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on December 31, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 44,200 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001774 · primarydocument.xml · derivative · entry 2 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,200 Underlying: Common Stock · 44,200 shares Expires 2031-02-26 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001774 · primarydocument.xml · nonDerivative · entry 1 Cotreau Violetta · CIK 0001841934 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,900 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.